Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for SUPN

Stock NameSupernus Pharmaceuticals Inc
TickerSUPN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS8684591089
LEI549300GRM36VBKISYJ58

Show aggregate SUPN holdings

News associated with SUPN

Contrasting Supernus Pharmaceuticals (NASDAQ:SUPN) and Evoke Pharma (NASDAQ:EVOK)
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) and Evoke Pharma (NASDAQ:EVOK – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. Volatility & Risk Supernus Pharmaceuticals has a beta […] - 2025-09-04 02:30:48
Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to “Hold” at Zacks Research
Zacks Research upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a strong sell rating to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports. Several other analysts also recently weighed in on SUPN. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $42.00 to $46.00 and gave […] - 2025-08-22 03:08:51
Maryland State Retirement & Pension System Trims Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Maryland State Retirement & Pension System lessened its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 13.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,094 shares of the specialty pharmaceutical company’s stock after selling 2,514 shares during […] - 2025-08-15 04:51:00
Supernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 1-Year High on Analyst Upgrade
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Free Report)’s share price hit a new 52-week high on Wednesday after Cantor Fitzgerald raised their price target on the stock from $42.00 to $46.00. Cantor Fitzgerald currently has an overweight rating on the stock. Supernus Pharmaceuticals traded as high as $41.51 and last traded at $42.29, with a […] - 2025-08-08 02:19:00
SUPN Crosses Above Average Analyst Target
In recent trading, shares of Supernus Pharmaceuticals Inc (Symbol: SUPN) have crossed above the average analyst 12-month target price of $40.20, changing hands for $42.44/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down - 2025-08-07 12:32:22
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at Wall Street Zen
Wall Street Zen upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a hold rating to a buy rating in a research note released on Saturday morning. Separately, Cantor Fitzgerald raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $42.00 price objective for the company in a […] - 2025-08-05 02:56:51
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by Wall Street Zen
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday. Supernus Pharmaceuticals Stock Performance Shares of Supernus Pharmaceuticals stock opened at $33.23 on Friday. The firm has a fifty day moving average […] - 2025-07-22 02:55:51
Allspring Global Investments Holdings LLC Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Allspring Global Investments Holdings LLC lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 6.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,353 shares of the specialty pharmaceutical company’s stock after selling 1,356 shares during the quarter. […] - 2025-07-10 04:34:50
Robeco Institutional Asset Management B.V. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Robeco Institutional Asset Management B.V. bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 8,151 shares of the specialty pharmaceutical company’s stock, valued at approximately $267,000. Other […] - 2025-07-03 05:08:49
Illinois Municipal Retirement Fund Has $927,000 Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Illinois Municipal Retirement Fund decreased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 2.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,303 shares of the specialty pharmaceutical company’s stock after selling 730 shares […] - 2025-07-02 05:28:54
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stake Boosted by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC increased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 12.5% during the first quarter, HoldingsChannel reports. The firm owned 24,881 shares of the specialty pharmaceutical company’s stock after acquiring an additional 2,762 shares during the period. Exchange Traded Concepts LLC’s holdings in Supernus Pharmaceuticals were worth $815,000 at […] - 2025-06-20 05:21:54
Azzad Asset Management Inc. ADV Acquires New Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Azzad Asset Management Inc. ADV acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,847 shares of the specialty pharmaceutical company’s stock, valued at approximately $552,000. A number of other […] - 2025-06-16 05:40:53
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Versant Capital Management Inc
Versant Capital Management Inc grew its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 6,931.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,125 shares of the specialty pharmaceutical company’s stock after purchasing an additional […] - 2025-06-06 05:45:08
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 19,824 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 24.7% during the 4th quarter, Holdings Channel reports. The firm owned 100,020 shares of the specialty pharmaceutical company’s stock after buying an additional 19,824 shares during the period. UBS […] - 2025-06-05 05:10:54
Millennium Management LLC Sells 222,273 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Millennium Management LLC decreased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 87.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,470 shares of the specialty pharmaceutical company’s stock after selling 222,273 shares during […] - 2025-06-05 04:25:01
Squarepoint Ops LLC Sells 475 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Squarepoint Ops LLC cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 2.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 20,492 shares of the specialty pharmaceutical company’s stock after selling 475 shares during the period. Squarepoint Ops LLC’s holdings in Supernus Pharmaceuticals were worth $741,000 at the end of […] - 2025-06-03 05:04:50
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,083 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 3.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 28,563 shares of the specialty pharmaceutical company’s stock after buying an additional 1,083 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Supernus Pharmaceuticals […] - 2025-05-26 04:47:00
Graham Capital Management L.P. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Graham Capital Management L.P. bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 6,908 shares of the specialty pharmaceutical company’s stock, valued at approximately $250,000. […] - 2025-05-19 05:26:49
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at StockNews.com
StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a research note published on Friday. Separately, Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. Get Our Latest Stock […] - 2025-05-19 02:38:47
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Northern Trust Corp
Northern Trust Corp boosted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 18.3% in the fourth quarter, HoldingsChannel reports. The firm owned 717,161 shares of the specialty pharmaceutical company’s stock after purchasing an additional 110,867 shares during the quarter. Northern Trust Corp’s holdings in Supernus Pharmaceuticals were worth $25,933,000 as […] - 2025-05-12 04:49:02
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by First Trust Advisors LP
First Trust Advisors LP lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 48.1% in the 4th quarter, Holdings Channel reports. The firm owned 27,019 shares of the specialty pharmaceutical company’s stock after selling 25,048 shares during the period. First Trust Advisors LP’s holdings in Supernus Pharmaceuticals were worth $977,000 […] - 2025-05-08 04:44:59
Barclays PLC Purchases 14,061 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Barclays PLC increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 12.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 122,849 shares of the specialty pharmaceutical company’s stock after buying an additional 14,061 shares during the period. Barclays PLC’s holdings in Supernus Pharmaceuticals were worth $4,442,000 at […] - 2025-04-28 04:59:03
Raymond James Financial Inc. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Raymond James Financial Inc. bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 189,364 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,847,000. Raymond James Financial Inc. owned approximately […] - 2025-04-24 04:41:05
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Position Raised by Invesco Ltd.
Invesco Ltd. lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 4.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 508,069 shares of the specialty pharmaceutical company’s stock after acquiring an additional 22,027 shares during the period. Invesco Ltd. owned 0.92% of […] - 2025-04-20 05:22:48
JPMorgan Chase & Co. Acquires 44,414 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
JPMorgan Chase & Co. grew its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 17.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 297,810 shares of the specialty pharmaceutical company’s stock after purchasing an additional 44,414 shares during the quarter. […] - 2025-04-15 04:32:48
Arrowstreet Capital Limited Partnership Purchases 77,393 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Arrowstreet Capital Limited Partnership increased its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 79.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 174,916 shares of the specialty pharmaceutical company’s stock after acquiring an additional 77,393 shares during […] - 2025-04-08 05:01:05
Prudential Financial Inc. Has $2.37 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Prudential Financial Inc. grew its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 14.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 66,733 shares of the specialty pharmaceutical company’s stock after buying an additional 8,352 shares […] - 2025-04-04 04:37:01
Sei Investments Co. Sells 16,825 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Sei Investments Co. cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 5.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 296,915 shares of the specialty pharmaceutical company’s stock after selling 16,825 shares during the period. Sei Investments Co.’s holdings in Supernus Pharmaceuticals were worth $10,736,000 at the end of […] - 2025-03-30 05:37:02
Swiss National Bank Has $3.92 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Swiss National Bank lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 0.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,400 shares of the specialty pharmaceutical company’s stock after purchasing an additional 800 shares during the quarter. […] - 2025-03-26 05:44:46
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Monday. Separately, Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. Get Our Latest […] - 2025-03-26 03:58:55

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc SUPN holdings

DateNumber of SUPN Shares HeldBase Market Value of SUPN SharesLocal Market Value of SUPN SharesChange in SUPN Shares HeldChange in SUPN Base ValueCurrent Price per SUPN Share HeldPrevious Price per SUPN Share Held
2025-11-13 (Thursday)5,371USD 238,687USD 238,687
2025-11-12 (Wednesday)5,371SUPN holding decreased by -17USD 239,654SUPN holding decreased by -8787USD 239,654-17USD -8,787 USD 44.62 USD 46.1101
2025-11-11 (Tuesday)5,388USD 248,441SUPN holding increased by 3826USD 248,4410USD 3,826 USD 46.1101 USD 45.4
2025-11-10 (Monday)5,388USD 244,615SUPN holding decreased by -3341USD 244,6150USD -3,341 USD 45.4 USD 46.02
2025-11-07 (Friday)5,388USD 247,956SUPN holding decreased by -6708USD 247,9560USD -6,708 USD 46.02 USD 47.265
2025-11-06 (Thursday)5,388SUPN holding decreased by -17USD 254,664SUPN holding increased by 34USD 254,664-17USD 34 USD 47.265 USD 47.1101
2025-11-05 (Wednesday)5,405SUPN holding decreased by -170USD 254,630SUPN holding decreased by -63145USD 254,630-170USD -63,145 USD 47.1101 USD 57
2025-11-04 (Tuesday)5,575SUPN holding decreased by -34USD 317,775SUPN holding increased by 5354USD 317,775-34USD 5,354 USD 57 USD 55.6999
2025-11-03 (Monday)5,609SUPN holding decreased by -34USD 312,421SUPN holding increased by 1322USD 312,421-34USD 1,322 USD 55.6999 USD 55.1301
2025-10-31 (Friday)5,643USD 311,099SUPN holding decreased by -7731USD 311,0990USD -7,731 USD 55.1301 USD 56.5001
2025-10-30 (Thursday)5,643USD 318,830SUPN holding increased by 4628USD 318,8300USD 4,628 USD 56.5001 USD 55.68
2025-10-29 (Wednesday)5,643USD 314,202SUPN holding increased by 14164USD 314,2020USD 14,164 USD 55.68 USD 53.1699
2025-10-28 (Tuesday)5,643SUPN holding increased by 51USD 300,038SUPN holding increased by 5228USD 300,03851USD 5,228 USD 53.1699 USD 52.72
2025-10-27 (Monday)5,592USD 294,810SUPN holding decreased by -615USD 294,8100USD -615 USD 52.72 USD 52.8299
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of SUPN by Blackrock for IE00B3VWM098

Show aggregate share trades of SUPN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-12SELL-17 44.620* 36.22 Profit of 616 on sale
2025-11-06SELL-17 47.265* 36.02 Profit of 612 on sale
2025-11-05SELL-17051.51543.110 43.951USD -7,472 35.96 Loss of -1,358 on sale
2025-11-04SELL-34 57.000* 35.85 Profit of 1,219 on sale
2025-11-03SELL-3456.17054.270 54.460USD -1,852 35.75 Loss of -636 on sale
2025-10-28BUY5153.17053.380 53.359USD 2,721 35.33
2025-10-24SELL-1752.83053.280 53.235USD -905 35.14 Loss of -308 on sale
2025-10-15BUY10249.27049.670 49.630USD 5,062 34.54
2025-10-02BUY1747.96048.640 48.572USD 826 34.38
2025-09-30BUY3447.79048.440 48.375USD 1,645 34.23
2025-09-11BUY6846.66046.720 46.714USD 3,177 33.86
2025-08-21SELL-1743.32043.540 43.518USD -740 33.80 Loss of -165 on sale
2025-07-31BUY5135.10035.920 35.838USD 1,828 33.74
2025-06-30SELL-3431.52031.810 31.781USD -1,081 33.88 Profit of 71 on sale
2025-06-25SELL-1731.24031.690 31.645USD -538 33.94 Profit of 39 on sale
2025-06-20SELL-3432.28033.300 33.198USD -1,129 33.98 Profit of 27 on sale
2025-05-23BUY1732.10032.200 32.190USD 547 34.23
2025-05-19SELL-1733.05033.550 33.500USD -569 34.28 Profit of 13 on sale
2025-05-15SELL-5132.48032.620 32.606USD -1,663 34.30 Profit of 87 on sale
2025-05-12SELL-1732.15032.320 32.303USD -549 34.36 Profit of 35 on sale
2025-05-09SELL-1731.70032.220 32.168USD -547 34.39 Profit of 38 on sale
2025-04-30SELL-1732.48032.800 32.768USD -557 34.54 Profit of 30 on sale
2025-04-24SELL-3431.35031.450 31.440USD -1,069 34.64 Profit of 109 on sale
2025-04-17SELL-1730.76031.150 31.111USD -529 34.85 Profit of 63 on sale
2025-04-15SELL-5131.46032.280 32.198USD -1,642 34.93 Profit of 139 on sale
2025-04-14SELL-5131.60032.280 32.212USD -1,643 34.96 Profit of 140 on sale
2025-04-09SELL-6831.76032.050 32.021USD -2,177 35.08 Profit of 208 on sale
2025-04-07SELL-11932.27034.260 34.061USD -4,053 35.16 Profit of 131 on sale
2025-04-04SELL-17032.74033.350 33.289USD -5,659 35.19 Profit of 323 on sale
2025-03-31BUY1732.75032.870 32.858USD 559 35.29
2025-03-19SELL-3432.03032.340 32.309USD -1,099 35.60 Profit of 112 on sale
2025-03-14SELL-10231.26031.570 31.539USD -3,217 35.75 Profit of 430 on sale
2025-03-13SELL-3431.17031.910 31.836USD -1,082 35.82 Profit of 135 on sale
2025-03-12SELL-57831.38031.980 31.920USD -18,450 35.88 Profit of 2,289 on sale
2025-03-07SELL-3432.07032.300 32.277USD -1,097 36.04 Profit of 128 on sale
2025-03-06SELL-5131.82032.200 32.162USD -1,640 36.10 Profit of 201 on sale
2025-03-03SELL-1731.74032.210 32.163USD -547 36.31 Profit of 70 on sale
2025-02-28SELL-10232.06032.080 32.078USD -3,272 36.38 Profit of 439 on sale
2025-02-26SELL-1731.91034.100 33.881USD -576 36.53 Profit of 45 on sale
2025-02-25SELL-5132.81033.500 33.431USD -1,705 36.59 Profit of 161 on sale
2025-02-18BUY8539.75039.990 39.966USD 3,397 36.83
2025-02-13BUY1739.53039.540 39.539USD 672 36.68
2025-02-12BUY1738.99039.490 39.440USD 670 36.63
2025-02-11BUY5138.65038.660 38.659USD 1,972 36.59
2025-02-06BUY15338.85039.530 39.462USD 6,038 36.47
2025-01-27BUY1739.41039.690 39.662USD 674 35.94
2024-12-30BUY8536.91037.280 37.243USD 3,166 35.73
2024-12-06BUY6837.17037.480 37.449USD 2,547 35.62
2024-12-05BUY1736.99037.440 37.395USD 636 35.57
2024-12-04BUY8537.15037.520 37.483USD 3,186 35.52
2024-11-29BUY8536.57037.050 37.002USD 3,145 35.34
2024-11-27BUY6836.99037.230 37.206USD 2,530 35.20
2024-11-26BUY1736.14036.590 36.545USD 621 35.16
2024-11-21BUY8535.82036.530 36.459USD 3,099 35.02
2024-11-20BUY5136.12036.500 36.462USD 1,860 34.96
2024-11-18BUY20435.25036.200 36.105USD 7,365 34.90
2024-11-12BUY13637.83037.990 37.974USD 5,164 34.71
2024-11-08BUY8536.60036.780 36.762USD 3,125 34.57
2024-11-07BUY25536.40037.750 37.615USD 9,592 34.43
2024-11-06BUY3437.75038.210 38.164USD 1,298 34.16
2024-10-31BUY1734.07035.030 34.934USD 594 34.05
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of SUPN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19122,1513301,18840.6%
2025-09-18121,7610267,52545.5%
2025-09-1770,393750204,21134.5%
2025-09-1692,8030275,02433.7%
2025-09-15117,876210292,58040.3%
2025-09-1256,904200164,68934.6%
2025-09-1180,78550192,70641.9%
2025-09-1097,2060247,18239.3%
2025-09-09103,40321,544214,67548.2%
2025-09-0894,0301,712217,57143.2%
2025-09-0565,260300193,61133.7%
2025-09-0487,4799,555199,60343.8%
2025-09-0371,5531,695171,33341.8%
2025-09-02151,60032,060318,69847.6%
2025-08-2978,3442,289147,46753.1%
2025-08-2896,124974162,32859.2%
2025-08-2798,4244,105244,87540.2%
2025-08-2668,3820134,61050.8%
2025-08-25114,0932,502258,41544.2%
2025-08-22170,4587,565320,38553.2%
2025-08-21126,8771,383256,89649.4%
2025-08-2097,552696267,86636.4%
2025-08-1996,5005,963208,44446.3%
2025-08-18104,7711,006285,51036.7%
2025-08-15124,03620,531334,97737.0%
2025-08-1483,0364,471360,72523.0%
2025-08-13143,7964,486408,81035.2%
2025-08-12120,422909359,23133.5%
2025-08-11112,8106,919330,27234.2%
2025-08-08228,44958,762395,64057.7%
2025-08-07334,0140923,64436.2%
2025-08-06692,0716,1101,667,36241.5%
2025-08-05248,6500476,50952.2%
2025-08-04162,9890229,99770.9%
2025-08-01250,1790326,68476.6%
2025-07-31433,277375912,33647.5%
2025-07-30158,3605215,82673.4%
2025-07-29188,5610455,53841.4%
2025-07-28160,9300241,81666.6%
2025-07-2598,8530302,32832.7%
2025-07-24122,0570194,07162.9%
2025-07-2362,1900125,50949.6%
2025-07-22141,5161,325343,16241.2%
2025-07-21197,0890471,96241.8%
2025-07-18105,7060300,27935.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.